EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Life Sciences
Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
- Our latest thinking
- Webinars
Our latest thinking
Pulse of the MedTech Industry Report 2024
2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
Under the microscope with Bayer’s Alok Kanti
As massive transformation continues to reshape the sector, we sat down with Alok Kanti, Bayer Inc.’s President & CEO, and Head of Pharmaceuticals.
A growing demand for cannabis testing is creating new ways for companies in this industry — and adjacent sectors — to grow.
58% of cannabis companies didn’t meet board expectations in 2022, finds EY survey
The EY Global Cannabis CEO Survey reveals that over half of cannabis companies underperformed relative to their board’s expectations in 2022, given the lasting impact of externals forces such as intense competition, price and margin pressures and complex regulations.
Will cannabis industry optimism cultivate sustainable progress?
Cannabis executives are excited about market opportunities. Even so, they face a barrage of complicating factors.
How life sciences businesses transform the tax and finance function
Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.
Webinars
How life sciences companies can navigate President Trump’s trade policies
In this webcast, panelists discuss the impacts of President Trump’s trade agenda on the supply chains of life sciences companies. Learn more.
Pulse on MedTech: How the industry is adapting to thrive
Current MedTech industry analysis on dealmaking, financing and commercial strategies, with insights on growth, AI, consumer and future state.
Under the microscope with Bayer’s Alok Kanti
As massive transformation continues to reshape the sector, we sat down with Alok Kanti, Bayer Inc.’s President & CEO, and Head of Pharmaceuticals.
How EY can help
-
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more -
The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more -
Biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. Find out how.
Read more -
EY MedTech report on dealmaking, financing and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
Read more